Merck's COVID treatment expected to launch in China on Friday

Esports Entertainment

11/01/2023 12:23

BEIJING, Jan 11 (Reuters) - Merck & Co's  MRK.N 
COVID-19 antiviral treatment molnupiravir is expected to be
launched in the Chinese market on Friday, Sinopharm's  1099.HK 
president Liu Yong was quoted as saying by state-backed media
outlet Kankan News on Wednesday.
    Merck said earlier in a filing that Sinopharm is the only
legally authorized distributor of molnupiravir in China, which
is sold under the brand name Lagevrio and was developed by Merck
and partner Ridgeback Biotherapeutics. 
 (Reporting by Ella Cao and Meg Shen
Editing by Mark Potter)
 ((Ella.Cao@thomsonreuters.com;))